+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07491497

Phase 12 Study of Oral TRI-611 in Adults with Advanced ALK-Positive Non-Small Cell Lung Cancer

Led by TRIANA Biomedicines, Inc. · Updated on 2026-09-03

160

Participants Needed

16

Research Sites

243 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and appropriate dosing of TRI-611, an oral ALK molecular glue degrader, in adults with ALK-positive non-small cell lung cancer NSCLC. This Phase 12 study also aims to understand how well TRI-611 works against tumors in this patient group. The study includes two parts first, testing different doses to find the best dose, and second, assessing the drugs effect in three groups based on prior treatments with ALK tyrosine kinase inhibitors TKIs. Participants will take TRI-611 continuously as long as their disease does not worsen and the treatment is tolerable. The study has four groups part 1 focuses on dose escalation and expansion, and part 2 includes cohorts defined by prior exposure to ALK TKIs, including lorlatinib and neladalkib. Visits occur approximately seven times during the first three months and then once at the start of each 28-day cycle thereafter. Participants will keep a diary to record each dose of the study medication. During the trial, participants will be monitored for side effects within 28 days after the first dose and have tumor responses evaluated about 16 weeks after dosing ends. Additional assessments include measuring drug levels in the blood and various long-term outcomes such as duration of response, disease control, progression-free survival, and overall survival, with follow-up lasting up to five years. Safety and tumor protein changes will also be observed to better understand TRI-611s effects.

CONDITIONS

Brief Title

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Research Team

T

TRIANA Clinical Trials

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here